Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Global Medical Genetics · 01.06.2024 · 11 (02) · 175-186
DOI: 10.1055/s-0044-1787301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Medical Genetics, erschienen am 01.06.2024. Verfasst von Wenchao Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, People's Republic of China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Anaplastic lymphoma kinase (ALK) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients.
Methods
The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study.
Results
In the current study, a total of 180 (3.20%) patients tested positive for ALK fusions in 5,622 NSCLC samples. Within the ALK-positive cohort, a total of 228 ALK fusions were identified. Furthermore, five novel ALK fusion partners, including DAB1-ALK, KCMF1-ALK, KIF13A-ALK, LOC643770-ALK, and XDH-ALK were identified. In cases with ALK fusion-positive, TP53 alterations were the most prevalent (26.3%), followed by CDKN2A (8.4%), epidermal growth factor receptor (EGFR, 5.6%), and ALK (5.6%). By contrast, EGFR alterations were most prevalent (51%) in patients with ALK fusion-negative NSCLC, followed by TP53 (42.7%), KRAS (11.6%), and CDKN2A (11.3%). A total of 10 cases where ALK fusion co-occurred with EGFR mutations were also identified. Notably, the ALK fusion positivity rate was higher in younger patients (p < 0.0001) and in female patients (p = 0.0429). Additionally, positive ALK test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff.
Conclusions
Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring ALK fusions within the context of precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, People's Republic of China.
- Department of Pathogenic Biology, Logistics University of Chinese People's Armed Police Force, Tianjin, People's Republic of China.
- Department of Oncology, Rongcheng County People's Hospital, Baoding, People's Republic of China.
- Department of Medicine, Yinfeng Gene Technology Co., Ltd., Jinan, People's Republic of China.
- Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
Zitieren
APA
Xia, W., Yang, J., Li, H., Li, L., & Liu, J. (2024). Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients. Global Medical Genetics, 11(02), 175-186. https://doi.org/10.1055/s-0044-1787301
Vancouver
Xia W, Yang J, Li H, Li L, Liu J. Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients. Global Medical Genetics. 2024;11(02):175-186. doi:10.1055/s-0044-1787301
BibTeX
@article{Xia2024,
author = {Xia, Wenchao and Yang, Jing and Li, Hongbin and Li, Ling and Liu, Jinfeng},
title = {Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients},
journal = {Global Medical Genetics},
year = {2024},
volume = {11},
number = {02},
pages = {175--186},
doi = {10.1055/s-0044-1787301}
}
EUVIMED